13 May 2013: SARS-Like Virus Vaccine Unlikely, Experts Say
"Health officials said vaccines were unlikely to play a role in controlling the outbreak"
"The thing that really takes time is the regulation aspect of it," said Ksiazek, professor in the dept. of pathology at the Univ. of Texas Medical Branch, describing the lengthy process of proving safety and efficacy in animal models before even thinking about testing in humans."
"There was no vaccine for SARS," Atmar said. "But the public health system was able to control the infection and basically eradicate it. That might also work for this new coronavirus."
"It's more than a matter of time and money. Coronaviruses, prickly pathogens that invade the body through the respiratory tract, are notoriously difficult when it comes to vaccine development, according to Atmar. "
"Some of the candidate vaccines for SARS caused lung damage in mice exposed to the virus."
"The concern is that if these vaccines were to be used in people, they could end up causing harm."
Este hilo resume los problemas de seguridad y problemas a los que se ha visto enfrentada por 18 años la vacuna de virus inactivado contra el Sars Cov1, Mers y ahora Sars Cov2,ampliamente distribuida por SINOPHARM en muchos países latinoamericanos. ¿Qué tanto se ha avanzado?
Desde la aparición del SARS en 2003 las vacunas inactivadas fueron la 1° opción d desarrollo, pero desde el comienzo demostraron tener problemas serios de seguridad.
Los cuales posiblemente estén ocurriendo hoy en día.
Durante el hilo, observe la progresión d los años.
CDC 2005 Desarrollo de la vacuna contra el SARS:
"La seguridad de la vacuna inactivada es una preocupación seria; algunas proteínas virales pueden inducir respuestas inmunes o inflamatorias dañinas, incluso causando enfermedades SIMILARES al SARS" 🤔
SARS vaccines: where are we?
"Data regarding the correlates of protection, animal models and the available evidence regarding potential vaccine ENHANCEMENT of SARS disease are discussed"
Inactivated virus vaccines
"However, despite high neutralizing antibody titers, protection was incomplete for all vaccine preparations and administration routes tested." 🤔@juancarlossaid
AdVs vectored SARS-CoV vaccines
"Interestingly, although the intramuscular route was more effective in inducing neutralizing SARS serum antibodies, the INTRANASAL route of administration induced IgA and was MORE EFFECTIVE in blocking SARS-CoV replication in nose and lung tissue"